American Vanguard Corp: Form 10-Q for the period ended Mar 31, 2021
Filed with the SEC on May 7, 2021 and accepted by EDGAR at May 7, 2021, 15:24 ET.
Management's discussion and analysis
As filed, 25,900 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
FORWARD-LOOKING STATEMENTS/RISK FACTORS:
The Company, from time-to-time, may discuss forward-looking statements including assumptions concerning the Company’s operations, future results and prospects. These forward-looking statements are based on current expectations and are subject to a number of risks, uncertainties and other factors. In connection with the Private Securities Litigation Reform Act of 1995, the Company provides the following cautionary statements identifying important factors which, among other things, could cause the actual results and events to differ materially from those set forth in or implied by the forward-looking statements and related assumptions contained in the entire Report. Such factors include, but are not limited to: product demand and market acceptance risks; the effect of economic conditions; weather conditions; changes in regulatory policy; the impact of competitive products and pricing; changes in foreign exchange rates; product development and commercialization difficulties; capacity and supply constraints or difficulties; availability of capital resources; general business regulations, including taxes and other risks as detailed from time-to-time in the Company’s reports and filings filed with the U.S. Securities and Exchange Commission (the “SEC”). It is not possible to foresee or identify all such factors. For more detailed information, refer to Item 1A., Risk factors and Item 7A., Quantitative and Qualitative Disclosures about Market Risk, in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020.
MANAGEMENT OVERVIEW
The Company’s Operations in the Context of the COVID-19 Pandemic
In March 2020, the World Health Organization categorized the novel coronavirus (COVID-19) as a pandemic, and it continues to spread across the world. To limit the spread of the contagion, governments have taken various actions to slow and otherwise control the spread of the pandemic, including the issuance of stay-at-home orders, social distancing guidelines and border restrictions. At its outset, the Company took swift action to understand, contain and mitigate the risks posed by this pandemic. Specifically, we formed the Pandemic Work Group with a mission to ensure the health and safety of the workforce while ensuring continuity of the business. In the workplace, we have designed and implemented protocols for social distancing, made provisions for the workforce to work remotely where possible, and established quarantine policies for those who present COVID-like symptom or may have been in touch with those who have. Further, the group keeps current with local, state, federal and international laws and restrictions that could affect the business; provides real-time information to the workforce; and draws from political commentary and news statements concrete directions on how best to continue operations. We have also prepared contingency plans to permit the continued operation of our factories, in the event that there are critical staffing issues due to attrition. In addition, in April 2020, we amended our credit facility to support future working capital needs (see note 10). Further, we continuously monitor supply chain, transport, logistics and border closures and have reached out to third parties to make clear that we are continuing to operate, that we have our own policies relating to health and are committed to compliance with COVID-19 policies of our business partners. Our CEO and the leader of the Pandemic Work Group is holding bi-weekly “state of the company” calls with the functional heads of our businesses across the globe to ensure that our information is shared in a timely manner and that our direction is clear.
It is important to understand that under applicable federal guidelines (at https://www.cisa.gov), the Company is part of the nation’s “critical infrastructure” and falls within three of the 16 sectors that are specially permitted to operate: “Food and Agriculture” sector (engaged in “the production of chemicals and other substances used by the food and agriculture industry, including pesticides, herbicides etc.”), the “Chemical” sector (“supporting the operation . . . of facilities (particularly those with high risk chemicals . . . whose work cannot be done remotely and requires the presence of highly trained personnel to ensure safe operations”) and the “Public Works and Infrastructure Support Services” sector (in support of exterminators, landscapers and others who provide services to residences and businesses). In issuing guidance on Coronavirus, former President Trump said, “If you work in a critical infrastructure industry, as defined by the Department of Homeland Security, such as healthcare services and pharmaceutical and food supply, you have a special responsibility to maintain your normal work schedule [emphasis added].” We have found that state COVID-19 orders and, indeed, even those of countries in which the outbreak has been most pronounced (e.g., Italy), have consistently excepted food supply as an area essential to the survival of its populations and, as such, had given special permission to companies, such as ours, to continue to operate during the pandemic.
In keeping with our charge to operate as an essential business and by virtue of our efforts to contain and mitigate the risks posed by the pandemic, we have been able to manage our business with minimal impact during the reporting period.
Overview of the Company’s Performance
While the first quarter of 2020 marked the start of a global pandemic that continued throughout the year, the first quarter of 2021 marked a favorable inflection point domestically with lower pandemic curves, ample supply of vaccines and easing of social restrictions. Within this context, the Company’s overall operating results for the first three months of 2021 improved considerably (both domestically and abroad), as compared with those of the same period of 2020. Net sales increased by 21 % ($116,155 as compared to $95,962) and net income increased by a factor of six (to $3,071 from $520).
On a consolidated basis, domestic sales rose 18% and international sales increased 27%, resulting in an overall net sales improvement of about 21%. The domestic net sales include an increase in royalty and license fees from our Envance proprietary solutions business of approximately $3,000. Cost of sales increased by 23% or $13,443 due not only to increased sales but also to changes in mix related to both products and territories and factory performance (including the addition of two new factory operations acquired as part of the Agrinos group). Cost of sales were 61% of sales in 2021, as compared to 60% for the same period of 2020. These factors, taken together, yielded a 18% increase in gross profit (to $45,131 from $38,381 in the comparable quarter of 2020), while average gross margin percent declined to 39% from 40% quarter-over-quarter. Operating expenses on an absolute basis increased by about 13%, as compared to the comparable quarter (to $41,444 from $36,545), largely due to the expanded scope of the Company’s global footprint following the acquisition of Agrinos biological products and the AgNova business in Australia. However, operating expenses as a percent of net sales dropped to 35% from 38% for the quarter indicating greater economies of scale for the period. Operating income for the period doubled (to $3,654 from $1,836), driven by the strong sales increase. The Company recorded significantly lower interest expense during the quarter as a result of working capital management in part driven by strong support from some of our biggest customers participating in early pay programs. These factors, coupled with a beneficial fair-value adjustment of an equity investment, yielded net income for the period of $3,071, a six-fold increase compared to $520 in the first quarter of 2020. Details on our financial performance are set forth below.
RESULTS OF OPERATIONS
Quarter Ended March 31:
| Net sales: | For the three months ended March 31, 2021 | 2020 | Change | % Change |
|---|---|---|---|---|
| US crop | $54,755 | $50,362 | $4,393 | 9% |
| US non-crop | 17,453 | 10,993 | 6,460 | 59% |
| Total US | 72,208 | 61,355 | 10,853 | 18% |
| International | 43,947 | 34,607 | 9,340 | 27% |
| Total net sales: | $116,155 | $95,962 | $20,193 | 21% |
| Cost of sales: | ||||
| US crop | $33,484 | $26,117 | $7,367 | 28% |
| US non-crop | 8,070 | 6,274 | 1,796 | 29% |
| Total US | 41,554 | 32,391 | 9,163 | 28% |
| International | 29,470 | 25,190 | 4,280 | 17% |
| Total cost of sales: | $71,024 | $57,581 | $13,443 | 23% |
| Gross profit: | ||||
| US crop | $21,271 | $24,245 | $(2,974) | -12% |
| US non-crop | 9,383 | 4,719 | 4,664 | 99% |
| Total US | 30,654 | 28,964 | 1,690 | 6% |
| International | 14,477 | 9,417 | 5,060 | 54% |
| Total gross profit: | $45,131 | $38,381 | $6,750 | 18% |
| Gross margin: | ||||
| US crop | 39% | 48% | ||
| US non-crop | 54% | 43% | ||
| Total US | 42% | 47% | ||
| International | 33% | 27% | ||
| Gross margin: | 39% | 40% |
Our domestic crop business recorded net sales that were about 9% higher than those of the first quarter 2020 ($54,755 as compared to $50,362). When viewed by type of product and crop, sales were mixed. During the first quarter, we saw an improved procurement pattern in the domestic market, as rising crop commodity prices caused growers and retailers to increase their purchases of crop protection inputs. Among our corn products, sales of our Impact® herbicide brands increased sharply, while those of our granular soil insecticides, including Aztec®, SmartChoice®, Force®, Thimet ® and Counter®, were up 8% as compared to the prior year. Soybean products, such as Scepter® and our post-emergent products Hornet® and Python® recorded higher sales, as compared to the same quarter in 2020. By contrast, we experienced a drop in net sales of Bidrin® due to carryover of inventory from last season when weather was dry and insect pressure was low. Further, soil fumigants posted a somewhat softer performance than the prior year due primarily to water allocation restrictions in California.
Cost of sales within the domestic crop business increased significantly both as a result of the increased volumes just discussed, and as a result of both a mix change and lower factory output, as compared to the first quarter of 2020. This generated a reduction of 12% in gross profit (from $24,245 in the first quarter of 2020 to $21,271 this year).
Our domestic non-crop business increased net sales by 59% (to $17,453 from $10,993) quarter-over-quarter. In this category, our Dibrom® mosquito adulticide and our pest strips business sales both grew, influenced by timing shifts in customer procurement. Royalty and license fees for our Envance proprietary solutions increased by approximately $3,000, as compared to the first quarter of last year. In addition, we recorded improved net sales from our nursery and ornamental business, as demand for homeowner garden and landscape products in big box stores recovered following the lifting of pandemic-related stay-at-home restrictions at certain locations.
Cost of sales within the domestic non-crop business rose by about 21% (from $6,274 to $8,070) quarter-over-quarter. This increase was volume driven. As indicated in the table, our costs increased at a slower rate than sales primarily because of the strong performance on royalty and license fees of the Envance technology business. As a result of these dynamics, gross profit for domestic non-crop increased by 99% (from $4,719 in 2020 to $9,383 in 2021).
Net sales of our international businesses rose by about 27% during the period ($34,607 in 2020 to $43,947 in 2021). Several factors contributed to this result. The addition of sales from our recently acquired AgNova business, an established crop protection business, effectively increased our Australian sales by seven times quarter over quarter. Mexico posted strongly improved sales with increased demand for granular insecticides, herbicides, and soil fumigants for use on high-value vegetable crops. In Brazil, net sales increased significantly despite delays in customer procurement arising from economic uncertainty and continued widespread COVID-19 limitations. Partially offsetting these gains, sales performance was slightly lower in Central America due to consolidation by certain AgriCenter suppliers, logistical difficulties arising from the pandemic and hurricane activity in Honduras.
Cost of sales in our international business increased by 17% (from $25,190 in 2020 to $29,470 in 2021), primarily driven by the addition of AgNova and by the strong growth of our other businesses in North and Central America. Gross profit for the international businesses increased by about 54% (from $9,417 in 2020 to $14,477 in 2021).
On a consolidated basis, gross profit for the first quarter of 2021 increased by 18% (from $38,381 in 2020 to $45,131 in 2021). The change in volume and mix, described above, had the impact of increasing absolute gross profit by 18% and reducing gross margin percentage by approximately 1%. As mentioned above, overall gross margin percentage ended at 39% in the first quarter of 2021, as compared to 40% in the first quarter of the prior year.
Operating expenses increased by $4,899 or 13% to $41,444 for the three months ended March 31, 2021, as compared to the same period in 2020. The differences in operating expenses by department are as follows:
| 2021 | 2020 | Change | % Change | |
|---|---|---|---|---|
| Selling | $11,133 | $10,474 | $659 | 6% |
| General and administrative | 15,848 | 12,504 | 3,344 | 27% |
| Research, product development and regulatory | 6,616 | 6,154 | 462 | 8% |
| Freight, delivery and warehousing | 7,847 | 7,413 | 434 | 6% |
| $41,444 | $36,545 | $4,899 | 13% |
- Selling expenses increased by $659 to end at $11,133 for the three months ended March 31, 2021, as compared to the same period of 2020. The main drivers were the increase in activities from the businesses newly acquired in the last quarter of 2020, increased in labor costs related to inflation and some key staff additions, and the unfavorable impact of the foreign currency exchange rates (as they relate to operating expenses of certain foreign subsidiaries). The increases were partially offset by the decrease in travel costs across all of our global operating subsidiaries primarily driven by pandemic restrictions on in person meetings and lower marketing expenses, and as a result of restrictions imposed in response to the COVID-19 pandemic.
- General and administrative expenses increased by $3,344 to end at $15,848 for the three months ended March 31, 2021, as compared to the same period of 2020. The main drivers were the addition of the entities acquired in the final quarter of 2020, the increase in short-term and long-term incentive compensation of $1,331, legal expenses of $860, and bad debt expense of $323. These increases were partially offset by decrease from reduced travel expenses in response to the COVID-19 pandemic.
- Research, product development costs and regulatory expenses increased by $462 to end at $6,616 for the three months ended March 31, 2021, as compared to the same period of 2020. The main drivers were the addition of new activities associated with acquired entities, general inflation in labor costs including the addition of some key technical headcount and in our product defense and product development costs relating to the commercialization of our SIMPAS delivery system.
- Freight, delivery and warehousing costs for the three months ended March 31, 2021 were $7,847 or 6.8% of sales as compared to $7,413 or 7.7% of sales for the same period in 2020. This change was primarily driven by the mix of product shipped and associated delivery destinations during the period.
On April 1, 2020, the Company made a strategic investment in Clean Seed Inc., in the amount of $1,190. During the three months ended March 31, 2021, the Company recorded positive fair value adjustments in the amount of $1,066.
During the three months ended March 31, 2021, a Paycheck Protection Program loan assumed on the acquisition of Agrinos in the fourth quarter of 2020 was fully extinguished with the majority of the balance forgiven and recorded as other income in the Company’s condensed consolidated statements of operations in the amount of $672.
Interest costs net of capitalized interest were $946 in the first three months of 2021, as compared to $1,508 in the same period of 2020. Interest costs are summarized in the following table:
Average Indebtedness and Interest expense
| Q1 2021 Average Debt | Interest Expense | Interest Rate | Q1 2020 Average Debt | Interest Expense | Interest Rate | |
|---|---|---|---|---|---|---|
| Revolving line of credit (average) | $125,299 | $860 | 2.7% | $165,076 | $1,496 | 3.6% |
| Amortization of deferred loan fees | — | 80 | — | — | 59 | — |
| Amortization of other deferred liabilities | — | 18 | — | — | 3 | — |
| Other interest (income) expense | — | 48 | — | — | 30 | — |
| Subtotal | $125,299 | $1,006 | 3.2% | $165,076 | $1,588 | 3.8% |
| Capitalized interest | — | (60) | — | — | (80) | — |
| Total | $125,299 | $946 | 3.0% | $165,076 | $1,508 | 3.7% |
The Company’s average overall debt for the three months ended March 31, 2021 was $125,299, as compared to $165,076 for the three months ended March 31, 2020. Our borrowings in the three months ended March 31, 2021 were lower mainly due to the increased participation from our biggest customers in our 2020 year-end early pay program, partially offset by the acquisition activity over the last 12 months and the associated investment in expanded working capital. As can be seen from the table above, our effective bank interest rate on our revolving line of credit was 2.7% for the three months ended March 31, 2021, as compared to 3.6% in 2020.
Income tax expense increased by $1,567 to $1,362 for the three months ended March 31, 2021, as compared to income tax benefit of $205 for the comparable period in 2020. The underlying effective tax rate for the three months ended March 31, 2021 and 2020 was 30.6% and 31.0%, respectively. During the three months ended March 31, 2020, the Company benefited from two discrete income tax benefits. First, the Company assessed its income tax positions to account for the Coronavirus Aid Relief and Economic Security Act (“CARES Act”) which was signed into law on March 27, 2020. A provision of the act modified the amount of interest deduction allowed and therefore reduced the Company’s 2019 Global Intangible Low Tax Income (“GILTI”) inclusion. Second, the Company benefited from the tax impact of the vesting of certain stock grants. These benefits in the prior year did not recur in the current year. The effective tax rate for all interim periods is based on the projected income for the full year and is subject to ongoing review and adjustment by management.
During the three months ended March 31, 2021 and 2020 we recognized a loss of $13 in each period, on our investment in the Hong Kong joint venture which is a 50% owned equity investment.
Our overall net income for the first three months of 2021 was $3,071 or $0.10 per basic and diluted share, as compared to $520 or $0.02 per basic and diluted share in the same quarter of 2020.
LIQUIDITY AND CAPITAL RESOURCES
The Company used cash of $32,600 in operating activities during the three months ended March 31, 2021, as compared to $14,069 during the three months ended March 31, 2020. Included in the $32,600 are net income of $3,221, plus non-cash depreciation, amortization of intangibles and other assets and discounted future liabilities, in the amount of $6,621, amortization of deferred loan fees of $81 and provision for bad debts in the amount of $682. Also included are stock-based compensation of $1,792, losses from equity method investment of $13, decrease in deferred income taxes of $269, change in equity investment fair value of $1,066, forgiveness of a PPP loan of $672, and an adjustment to the bargain purchase gain of $33. These together provided net cash outflows of $10,436, as compared to $7,131 for the same period of 2020.
During the first three months of 2021, the Company increased working capital by $38,589, as compared to $14,161 during the same period of the prior year. Included in this change: inventories increased by $9,615 (normal at this point in the season), as compared to $16,446 for the first quarter of 2020. Deferred revenue decreased by $11,293, as compared to $2,342 in the same period of 2020, driven by customer decisions regarding demand, payment timing and our cash incentive programs. Our accounts payable balances increased by $2,293, as compared to $1,617 in the same period of 2020. Accounts receivables increased by $30,422, as compared to $6,578 in the same period of 2020. This is primarily driven by increased group sales and strong international growth. Prepaid expenses increased by $1,052, as compared to $776 in the same period of 2020. Income tax receivable decreased by $638, as compared to increasing by $597 in the prior year. Accrued programs increased by $7,770, as compared to $6,016 in the prior year, which is normal at this point in the growing season. Finally, other payables and accrued expenses decreased by $1,187, as compared to $2,094 in the prior year.
With regard to our program accrual, the increase (as noted above) primarily reflects our mix of sales and customers in the first quarter of 2021, as compared to the prior year. The Company accrues programs in line with the growing season upon which specific products are targeted. Typically crop products have a growing season that ends on September 30th of each year. During the first quarter of 2021, the Company made accruals for programs in the amount of $18,815 and made payments in the amount of $11,060. During the first quarter of the prior year, the Company made accruals in the amount of $17,189 and made payments in the amount of $11,192.
Cash used for investing activities was $2,904 for the three months ended March 31, 2021, as compared to $2,980 for the three months ended March 31, 2020. The Company spent $2,904 on fixed assets acquisitions primarily focused on continuing to invest in manufacturing infrastructure and $41 on patents for the Envance technology business.
During the three months ended March 31, 2021, financing activities provided $32,853, from borrowings on the Company’s senior credit facility, as compared to $16,641 for the same period of the prior year. In the first quarter of 2021, we paid dividends to stockholders amounting to $593, as compared to $582 in the same period of 2020.
The Company has a revolving line of credit shown as long-term debt in the condensed consolidated balance sheets at March 31, 2021 and December 31, 2020. The debt is summarized in the following table:
| Long-term indebtedness | March 31, 2021 | December 31, 2020 |
|---|---|---|
| Revolving line of credit | $143,800 | $107,900 |
| Deferred loan fees | (377) | (458) |
| Total indebtedness | $143,423 | $107,442 |
At March 31, 2021, the Company is compliant with all covenants to its Senior Credit Facility. Based on its performance against the most restrictive covenants in the Credit Agreement (see Note 10), the Company had the capacity to increase its borrowings by up to $50,993, according to the terms thereof. This compares to an available borrowing capacity of $86,736 as of December 31, 2020 and $39,552 as of March 31, 2020. The level of borrowing capacity is driven by three factors: (1) our financial performance, as measured in EBITDA for both the trailing twelve-month period and proforma basis arising from acquisitions, (2) net borrowings, (3) the leverage covenant (the Consolidated Funded Debt Ratio).
We believe that anticipated cash flow from operations, existing cash balances and available borrowings under our amended senior credit facility will be sufficient to provide us with liquidity necessary to fund our working capital and cash requirements for the next twelve months.
RECENTLY ISSUED ACCOUNTING GUIDANCE
Please refer to Note 15 in the accompanying Notes to the Condensed Consolidated Financial Statements for recently issued and adopted accounting standards.
CRITICAL ACCOUNTING POLICIES AND ESTIMATES
The Company continually re-assesses the critical accounting policies used in preparing its financial statements. In the Company’s Form 10-K filed with the SEC for the year ended December 31, 2020, the Company provided a comprehensive statement of critical accounting policies. These policies have been reviewed in detail as part of the preparation work for this Form 10-Q. After our review of these matters, we have determined that, during the subject reporting period, there has been no material change to the critical accounting policies that are listed in the Company’s Form 10-K for the year ended December 31, 2020.
Certain of the Company’s policies require the application of judgment by management in selecting the appropriate assumptions for calculating financial estimates. These judgments are based on historical experience, terms of existing contracts, commonly accepted industry practices and other assumptions that the Company believes are reasonable under the circumstances. These estimates and assumptions are reviewed periodically, and the effects of revisions are reflected in the condensed consolidated financial statements in the period that revisions are determined to be necessary. Actual results may differ from these estimates under different outcomes or conditions.
Market risk
As filed, 1,173 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company is exposed to market risk related to changes in interest rates, primarily from its borrowing activities. The Company’s indebtedness to its primary lender is evidenced by a line of credit with a variable rate of interest, which fluctuates with changes in the lender’s reference rate. For more information, please refer to the applicable disclosures in the Company’s Form 10-K filed with the SEC for the year ended December 31, 2020.
The Company faces market risk to the extent that changes in foreign currency exchange rates affect our non-U.S. dollar functional currency as to foreign subsidiaries’ revenues, expenses, assets and liabilities. The Company currently does not engage in hedging activities with respect to such exchange rate risks.
Assets and liabilities outside the U.S. are located in regions where the Company has subsidiaries or joint ventures: Central America, South America, North America, Europe, Asia, and Australia. The Company’s investments in foreign subsidiaries and joint ventures with a functional currency other than the U.S. dollar are generally considered long-term. Accordingly, the Company does not hedge these net investments.
Controls and procedures
As filed, 1,058 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
As of March 31, 2021, the Company has a comprehensive set of disclosure controls and procedures designed to ensure that all information required to be disclosed in our filings under the Securities Exchange Act (1934) is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms. As of March 31, 2021, the Company’s management, including the Company’s Chief Executive Officer and Chief Financial Officer, has concluded, based on their evaluation, that the Company’s disclosure controls and procedures are effective to provide reasonable assurance of the achievement of the objectives described above.
There were no changes in the Company’s internal controls over financial reporting that occurred during the most recent quarter that have materially affected, or are reasonably likely to materially affect, the Company’s internal controls over financial reporting.
PART II. OTHER INFORMATION
The Company was not required to report any matters or changes for any items of Part II except as disclosed below.
Risk factors
As filed, 1,737 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.
The Company continually re-assesses the business risks, and as part of that process detailed a range of risk factors in the disclosures in American Vanguard’s Report on Form 10-K for the fiscal year ended December 31, 2020, filed on March 31, 2021. In preparing this document, we have reviewed all the risk factors included in that document and find that there are no material changes to those risk factors, except for the following:
The Covid-19 pandemic is creating risk, uncertainty and adverse conditions in many industries both here and abroad. The Company is closely monitoring the impact of the COVID-19 pandemic on all aspects of its business, including how the pandemic will impact its customers, business partners, and employees. While the Company did not incur significant disruptions from the COVID-19 pandemic during the three months ended March 31, 2021, the Company is unable to predict the impact that the pandemic will have on its financial condition, results of operations and cash flows due to numerous uncertainties. The extent to which the COVID-19 pandemic impacts the Company’s operations and those of its customers will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact, and the direct and indirect economic effects of the pandemic and containment measures, among others. There is no guarantee that the Company will be able to operate without material disruption for the duration of the pandemic or that its financial conditions and results of operations will not be materially adversely affected by the pandemic in future quarters.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2021-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2021-01-01 to 2021-03-31 | $116.2m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months2021-01-01 to 2021-03-31 | $71.0m | us-gaap:CostOfRevenue |
| Gross profit | 3 months2021-01-01 to 2021-03-31 | $45.1m | us-gaap:GrossProfit |
| Operating income | 3 months2021-01-01 to 2021-03-31 | $3.7m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2021-01-01 to 2021-03-31 | $946.0k | us-gaap:InterestExpense |
| Income tax | 3 months2021-01-01 to 2021-03-31 | $1.4m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2021-01-01 to 2021-03-31 | $3.1m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2021-01-01 to 2021-03-31 | $0.10 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2021-01-01 to 2021-03-31 | $0.10 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2021-01-01 to 2021-03-31 | 30,523,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2021-01-01 to 2021-03-31 | −$32.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Dividends paid | 3 months2021-01-01 to 2021-03-31 | $593.0k | us-gaap:PaymentsOfDividends |
| Cash and equivalents | At period end2021-03-31 | $13.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2021-03-31 | $365.9m | us-gaap:AssetsCurrent |
| Total assets | At period end2021-03-31 | $710.0m | us-gaap:Assets |
| Current liabilities | At period end2021-03-31 | $166.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2021-03-31 | $350.0m | us-gaap:Liabilities |
| Long-term debt | At period end2021-03-31 | $143.4m | us-gaap:LongTermDebtNoncurrent |
| Short-term borrowings | At period end2021-03-31 | $0 | us-gaap:ShortTermBorrowings |
| Shareholders' equity | At period end2021-03-31 | $360.0m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001564590-21-025510. Last ingested by Listed: Nov 11, 2026, 00:16 ET. Listed shows no prices and gives no investment advice.